

Review

Genetic and Physiological Factors Affecting Human Milk Production and Composition

Yarden Golan and Yehuda G. Assaraf *

The Fred Wyszowski Cancer Research Laboratory, Department of Biology, Technion-Israel Institute of Technology, Haifa 3200003, Israel; golanyar@campus.technion.ac.il

* Correspondence: assaraf@technion.ac.il; Tel.: +972-4829-3744; Fax: +972-4822-5153

Received: 26 April 2020; Accepted: 19 May 2020; Published: 21 May 2020

Abstract: Human milk is considered the optimal nutrition for infants as it provides additional attributes other than nutritional support for the infant and contributes to the mother's health as well. Although breastfeeding is the most natural modality to feed infants, nowadays, many mothers complain about breastfeeding difficulties. In addition to environmental factors that may influence lactation outcomes including maternal nutrition status, partner's support, stress, and latching ability of the infant, intrinsic factors such as maternal genetics may also affect the quantitative production and qualitative content of human milk. These genetic factors, which may largely affect the infant's growth and development, as well as the mother's breastfeeding experience, are the subject of the present review. We specifically describe genetic variations that were shown to affect quantitative human milk supply and/or its qualitative content. We further discuss possible implications and methods for diagnosis as well as treatment modalities. Although cases of nutrient-deficient human milk are considered rare, in some ethnic groups, genetic variations that affect human milk content are more abundant, and they should receive greater attention for diagnosis and treatment when necessary. From a future perspective, early genetic diagnosis should be directed to target and treat breastfeeding difficulties in real time.

Keywords: Human milk; nutrition; nutrigenomics; nutrigenetics

1. Introduction

1.1. Hormones Inducing and Sustaining Human Milk Production: Prolactin and Oxytocin

The mammary gland is a unique glandular organ that undergoes major morphologic and physiologic changes during the life of the organism. During puberty, hormones including estrogen initiate mammary gland development to support lactation [1–3]. Later, during pregnancy, elevated levels of progesterone and prolactin initiate the alveolar development in the mammary gland as well as the proliferation of mammary gland epithelial cells [4]. The lactogenic hormones estrogen, progesterone, and prolactin and metabolic hormones such as insulin are required for the differentiation of mammary epithelial secreting cells, which are capable of synthesizing and secreting specific milk components. This process is termed “secretory differentiation” and it continues during pregnancy [5,6]. After delivery, hormonal changes initiate milk secretion from mammary gland epithelial cells, a stage termed “secretion activation”. In this stage, the levels of progesterone decrease dramatically, whereas prolactin, insulin, and cortisol are essential for regulation of this crucial phase [5,6]. In addition, oxytocin, a nine amino acids neuropeptide hormone that is synthesized in the hypothalamus, is secreted by the posterior pituitary to the circulation as a trigger for infant suckling the mother's nipple [7–9]. Oxytocin is responsible for the induction of contraction of myoepithelial cells of the mammary gland, resulting in milk ejection [7], or the “let-down” reflex that releases the

milk from the ducts [8]. In this respect, oxytocin-deficient mice failed to lactate their pups, and this important function of oxytocin could not be compensated by other mechanisms [8]. The complex hormonal regulation of breast milk production and secretion may largely affect the outcome of lactation. However, very little is known about how genetic variations in these key factors for lactation, affect human breastfeeding success.

1.2. Physiological Changes in Breast Milk Composition

Breastfeeding has numerous positive impacts on infants beyond the nutritional value of milk. Human milk is the best nutrition for infants during the first six months after birth and it is highly recommended to continue breastfeeding along with supplementary foods up to two years of age [10]. The composition of the transitional and mature human milk differs largely from the colostrum, which is secreted in the first days of lactation and contains many immunologic components [11]. The concentration of some human milk components including vitamins B₆, B₁₂, and vitamin C (ascorbic acid) declines with the duration of breastfeeding, until weaning [12]. Furthermore, calcium, iron, zinc, and copper concentrations gradually decrease throughout lactation [13]. Additionally, the concentration of some nutrients in the milk depends on the mother's diet [14,15]. In most cases, the transport of nutrients to the milk will continue even upon maternal deficit, and milk production may lead to reduction of the mother's reserves. However, in some cases of inadequacy of maternal diet, the infant may experience inadequate levels of micronutrients, which might be critical for the infant's health [16]. Vitamin B₁₂ levels were shown to be in correlation to the mothers' diet, with lower concentrations in milk of vegetarian mothers compared to omnivorous mothers [17]. Vitamin K as well as vitamin D concentrations in human milk were found to be non-sufficient, thus they should be added to the infant's diet right after birth [18,19]. With the current introduction of new analytic techniques for the reliable quantification of nutrient levels in human milk [20], our knowledge about the normal variation and adequate levels of the various components in breast milk will increase, towards the optimization of the nutritional status of the infants. The physiologic decrease in some human milk components is reasonable when taking into consideration that infants are able to consume other food types when reaching the age of ~6 months. Therefore, the mother's milk is not the only nutritional source for the infant at this age, and the infant is supposed to obtain the deficient nutrients from supplementary foods.

2. Materials and Methods

The aim of the present review paper was to summarize the genetic variations found to affect human milk production or content. An Internet search using Google Scholar and PubMed databases was used to identify and download abstracts and papers related to this topic using various key terms, including genes/genetic/variations/mutations/single nucleotide polymorphism (SNP) and human milk/breast milk.

3. Genetic Variations that Affect Human Milk Composition

In addition to maternal nutrition and hormonal regulation that may affect both breast milk volume and composition, certain genetic variations were recently reported to affect human milk composition [21–23]. Table 1 depicts the summary of variations that were associated with changes in human milk components. These genetic variations are detailed in the following section.

3.1. *ZnT2 (SLC30A2) Mutations and Transient Neonatal Zinc Deficiency (TNZD)*

In 2006, the first mutation in the *SLC30A2/ZnT2* gene was found to be associated with transient neonatal zinc deficiency (TNZD), a disorder that leads to severe zinc deficiency exclusively in breastfed infants [24]. Since this pioneering report, at least 10 distinct mutations in *SLC30A2/ZnT2* were identified in mothers producing zinc-deficient milk, and consequently in the blood of their exclusively breastfed infants, which developed severe zinc deficiency [25–33]. This disorder was termed TNZD, as the symptoms associated with zinc deficiency resolved upon zinc supplementation

of the infants during the lactation period and these infants were completely cured after weaning. We have recently proposed that a haploinsufficiency state occurs in women harboring heterozygous mutations in *SLC30A2/ZnT2*, which implies that a single gene copy of the wild type (WT) allele is not sufficient for the secretion of zinc into the milk to meet the infant's nutritional needs [32]. We have further reported that the frequency of individuals harboring TNZD causing alleles was as high as 1 in 2334 individuals from various ethnic groups [34]. Furthermore, the frequency of the specific founder p.G87R mutation in the Ashkenazi Jewish population was even higher and attained a striking frequency of 1 in 576 individuals (unpublished data); this frequent mutation is known to cause TNZD [29]. In this respect, we previously discovered that the heterozygous G87R mutation inflicts a dominant negative effect on the WT ZnT2 allele via dimerization, hence disrupting its zinc transport activity [29,35].

Additionally, although ZnT2-KO mice display only a modest reduction in the milk zinc content (~30% reduction), presumably due to the compensatory transport function of ZnT4, major deleterious effects were reported on both mammary gland development and function as well as on milk volume and composition including protein, fat, and lactose content during lactation [36]. If these findings also reflect the function of ZnT2 in women's mammary gland, it may negatively affect not only human milk composition, but also the actual breastfeeding ability. Importantly, these findings might explain the relatively low number of TNZD cases that were reported in the literature in contrast to the high frequency of TNZD causing alleles in the general population [34]. If women harboring loss of function (LoF) mutations in *SLC30A2/ZnT2* also suffered from low milk supply, supplementary foods must be provided to the infant relatively early (i.e., baby formula) which will therefore mask the zinc deficiency in the milk. In addition to LoF mutations, some single nucleotide polymorphisms (SNPs) were identified in *SLC30A2/ZnT2*. In one case, the L23P SNP was associated with low zinc levels in human milk [37]. Owing to the higher frequency of SNPs in some ethnic groups, it is highly important to investigate their effect on breast milk zinc concentration in order to prevent deficiencies in the nursing infants. We recently established a genetic test for the detection of maternal *SLC30A2/ZnT2* mutations, using RNA from cells that are present in the mother's milk, for early diagnosis and prevention of TNZD [32]. To date, infants are diagnosed only after they show symptoms of severe zinc deficiency, which include severe erythematous scaly rash involving the face, neck, and diaper area. However, asymptomatic cases of moderate zinc deficiency are undiagnosed and untreated [32]. The recommended treatment for TNZD was zinc supplementation (5 mg/day) together with continuing breastfeeding until weaning [32].

3.2. *ABCG2 (BCRP) – Riboflavin Secretion and Milk Volume*

The gene expression of the ATP-driven, multidrug efflux transporter, breast cancer resistance protein (BCRP/*ABCG2*) was shown to be strongly induced in the mammary gland during pregnancy and lactation in mice, cows, and humans [38]. In mice, knock-out of *BCRP1* lead to a 63-fold reduction in riboflavin (vitamin B₂) concentration and 3-fold reduction in biotin levels in the milk [38]. Interestingly, heterozygous mice pups (*Bcrp1^{+/-}*), which were nursed by *Bcrp1^{-/-}* dams, showed only a modest reduction in their plasma riboflavin concentration 7–12 days after birth, probably owing to conversion of flavin adenine dinucleotide (FAD) (which was found in normal levels in milk of *Bcrp1^{-/-}* dams that were fed with normal diet), the enzyme cofactor of riboflavin [38]. Hence, two distinct transport systems are apparently operating in the lactating breast epithelium, which secrete both riboflavin and its enzyme cofactor FAD. In contrast, pups nursing from WT or *Bcrp1^{-/-}* dams consuming a riboflavin-deficient diet were reported to suffer from riboflavin-deficiency symptoms such as growth retardation, fatty degeneration of liver, and severe anemia [38]. These observations are in accordance with the importance of riboflavin for infant development, which makes it reasonable to preserve two independent pathways for riboflavin transport into the milk. Consistently, in Holstein cattle breed, genetic variations in *ABCG2* were associated with milk yields and fat as well as milk protein percentage [39,40]. In women, the *ABCG2* c.421C > A polymorphism was shown to affect the export of nifedipine (a calcium channel blocker used to treat hypertension during breastfeeding) to the milk [41]. This SNP, which is highly abundant in different ethnic groups,

was shown to alter the activity of ABCG2, leading to significant changes in nifedipine pharmacokinetics [41]. It was specifically shown that mothers harboring the heterozygous c.421C > A polymorphism have a significantly higher milk to plasma nifedipine ratio than mothers harboring the c.421CC genotype. Further research is needed to evaluate the effect of this variant and other genetic variations in ABCG2 on riboflavin concentration in human milk and how a maternal diet may affect the riboflavin concentration in the presence of these SNPs. Additionally, these results show that genetic variations in transporters, which are highly expressed in the mammary gland during lactation, such as ABCG2, affect the pharmacokinetics of drugs to the milk, and emphasize the importance of understanding the effect of these variations not only on the transport of nutrients, but also on drug delivery into the milk.

3.3. Genetic Variations in the Sodium Iodide Symporter (NIS/SLC5A5) and Iodine Deficiency in Human Milk

Iodine uptake from human milk is crucial for the production of iodine-containing thyroid hormones and, consequently, normal cognitive and physical development of infants [42]. Specifically, thyroid hormones are required for proper neuronal development [43–45]. Iodine concentration in human milk depends on the maternal iodine status, and it was reported to increase with iodine supplementation or consumption of iodized salt [46]. However, iodine concentration is 20–50-fold higher in human milk when compared with its plasma concentration [46]. It is also thought that it might be transported to the milk even under maternal iodine deficiency, owing to depletion of maternal reserves [42]. Iodine is actively transported into the mammary gland epithelial cells, mainly by the sodium iodide symporter (NIS/SLC5A5), the expression of which is upregulated in the mammary gland during lactation [42]. To the best of our knowledge, no iodine exporter was reported to be expressed in the human mammary gland during lactation and the mechanism of iodine transport from the cytoplasm of mammary gland epithelial cells into the milk remains to be established. RT-PCR analyses in the mammary glands of lactating mice showed the expression of multiple Ca⁺⁺-activated Cl⁻ channels (CaCC) including TMEM16A, BEST1, and BEST3 [47]. Remarkably, lactating mouse epithelial cells displayed an anion permeability in the sequence: I⁻ > NO₃⁻ > Br⁻ > Cl⁻ >> glutamate; thus, such CaCC could readily function as efflux transporters of iodine into the milk. In addition, iodine was shown to exit the apical membrane through Pendrin, Ano1, and CFTR to the milk in mice [48]. Looking at the gene expression database from human milk fat globules [49], the iodine exporters that are expressed in this database during lactation are TMEM16A and at very low levels BEST1, suggesting these genes as candidates for iodine to human milk (see gene expression table in [47]). Notably, NIS is expressed in the mammary gland only late in pregnancy and during lactation [50]. Lactation is critical in mammals because maternal milk is the only source of iodine for the newborn. Importantly, when non-lactating mouse dams were treated with oxytocin, their mammary tissue accumulated significantly more radioiodide because NIS expression was induced. In contrast, ovariectomized mice required oxytocin, estradiol, and prolactin to express NIS in their mammary glands [50].

NIS functions as a sodium-iodide co-transporter, exploiting the large blood sodium gradient to drive a concentrative iodide uptake [51]. Iodide transport defect (ITD), a rare autosomal recessive condition that leads to congenital goiter or hypothyroidism, may be a result of homozygous or compound mutations in the NIS transporter. To date, 14 ITD missense and nonsense mutations have been reported that affect the NIS coding sequence (Table 1) [51]. In addition, one mutation in the 5' untranslated region (a C→T transition at position-54) has also been reported [52]. Recently, a woman carrying the abovementioned homozygous T354P mutation in the NIS transporter was reported to produce iodine-deficient human milk [53]. In this case, the mother was treated with a daily dose of 50 mg potassium iodide starting on the fifth day postpartum until six weeks postpartum, when breastfeeding was ceased [53]. Further research is needed to assess the impact of heterozygous mutations or other genetic alterations in the NIS transporter, which do not result in ITD, and thus are not diagnosed in most cases, based on human milk iodine concentration.

Table 1. Genetic variations that were associated with changes in human milk components, as well as the effect on the infant and suggested treatment. LoF, loss of function; BCRP, breast cancer resistance protein; ABCG2, ATP-driven, multidrug efflux transporter; ITD, iodide transport defect; SNP, single nucleotide polymorphism; HMO, human milk oligosaccharide.

Gene Name	Protein Name	Effect of Mutations on Human Milk	The Effect on the Infant or Related Disease	Treatment
<i>SLC30A2</i>	ZnT2	LoF homozygous mutation in ZnT2 were found in mothers producing zinc-deficient human milk [25–33].	Transient neonatal zinc deficiency (TNZD), a disorder that leads to severe zinc deficiency in exclusively breastfed infants	Zinc supplementation (5 mg/day) and continuing breastfeeding [32]. No supplementation is needed after weaning.
<i>ABCG2</i>	BCRP	Mothers harboring the c.421C > A polymorphism in ABCG2, secreted threefold more nifedipine to human milk [41].	Unknown	
<i>SLC5A5</i>	Sodium iodide symporter (NIS)	Mother carrying homozygous T354P mutation in the NIS transporter was reported to produce iodine-deficient milk. Other known LoF mutations in <i>SLC5A5</i> : V59E [54], G93R [51], R124H [55], Δ143-323 [56], Q267E [57], V270E [58], C272X [59], Δ287-288 [60], T354P [61], G395R [62], Δ439-443 [63], G543E [64], fs151X [65], and Y531X [65].	The mother was diagnosed with ITD, treated with levothyroxine from the age of five years old, therefore, iodine supplementation was given after birth to prevent deficiencies in the infant.	Mother supplementation with 50 mg potassium iodide tablet daily starting on the fifth day postpartum to increase iodine concentration in human milk.
<i>MTHFR</i>	Methylene tetrahydrofolate reductase	The MTHFR 677C > T SNP was associated with higher levels of human milk unmetabolized folic acid (UMFA) [41].	Unknown	
<i>MTHFD1</i>	Methylene tetrahydrofolate dehydrogenase 1	rs1076991, rs2983733, rs2987981, rs8003379, and rs17824591 SNPs in the methylene tetrahydrofolate dehydrogenase 1 (<i>MTHFD1</i>) gene were found to be associated with very high human milk choline concentrations in three subjects [22].	Unknown	
<i>FADS1</i> and <i>FADS2</i>	Fatty acid desaturase 1/2	The minor allele homozygotes of rs174553 (GG), rs99780 (TT), and rs174583 (TT) were associated with significantly lower 14:0, arachidonic (ARA, 20:4) and eicosapentanoic acid (EPA, 20:5), but higher 20:2 (n – 6) fatty acid in human milk [66]. Mothers carrying the minor homozygous allele G/G of rs174575, showed lower ARA, EPA, and docosahexanoic acids (DHA,	Mothers carrying genetic variants associated with lower FADS1 activity (regulating AA and EPA synthesis), higher FADS2 activity (regulating DHA synthesis), and with higher EPA/AA and DHA/AA ratios in colostrum showed a	

		22:6 (n = 3)) and 22:5 (n = 3) levels in human milk [66]. Mothers carrying FADS1 rs174561, FADS2 rs174575, and intergenic rs3834458 minor alleles were found to have lower proportions of DHA in human milk [23].	significant advantage in cognition at 14 months.
FUT2	Fucosyltransferase 2	Nonsense mutation W143X that introduces a premature stop codon in the FUT2 gene (rs601338) abolished the ability to synthesize α (1-2)-fucosylated HMOs (non-secretor status). Non-secretors were found to express less HMOs compared to mothers with secretor status (active FUT2) [67–70]. In addition, maternal secretor status was shown to be associated with the human milk microbiota composition [71].	Infants fed by non-secretor mothers, were delayed in the establishment of their gut microbiota, specifically <i>bifidobacterial-laden</i> [72,73].

3.4. Human Milk Choline Concentrations

Although not a vitamin, choline is an essential nutrient for infants as it is required for their rapid growth and development [74,75]. Choline is essential for many physiological functions. For example, choline is part of the neurotransmitter acetylcholine, as well as the phospholipid phosphatidylcholine, which is a major lipid component in membranes [76]. *MTHFD1* encodes for a protein that has three distinct enzymatic reactions in the interconversion of one-carbon derivatives of tetrahydrofolate, which are substrates for methionine, thymidylate, and *de novo* purine syntheses [77]. SNPs in *MTHFD1* were shown to increase choline concentration in human milk [22]. Using cultured mammary tissues derived from 12–14 day pregnant mice, the impact of the three primary lactogenic hormones prolactin, insulin, and cortisol on choline uptake and incorporation into phospholipids was determined [78]. Insulin alone or in the presence of cortisol and/or prolactin was the only hormone that enhanced choline accumulation in aqueous tissue fractions. In contrast, when present with insulin and cortisol, prolactin was the only lactogenic hormone that stimulated the incorporation of choline into the lipid fraction of mammary tissues. Furthermore, choline uptake was found to be sodium- and time-dependent. Collectively, these findings suggest the existence of a sodium-dependent active transporter for choline in the mouse mammary gland that is specifically stimulated by cortisol, whereas prolactin appears to only stimulate the incorporation of choline into phospholipids [78]. Further studies are required to better characterize the transport mechanism of choline into human milk.

3.5. Folate Content in Human Milk

Reduced folates are essential as one-carbon donors for DNA, RNA, and protein synthesis. Folate receptor 1 (*FOLR1*) was found to be one of the highly expressed genes during lactation in human milk cells [79], and was suggested to be a regulator of milk protein synthesis. In goats, *FOLR1* polymorphism was associated with milk production traits [80], suggesting a possible role for this gene in milk production. Although homozygous mutations and SNPs in *FOLR1* were reported in the literature to cause progressive ataxia and myoclonic epilepsy and elevated levels of homocysteine, respectively, the role of heterozygous mutations or SNPs in *FOLR1* on human milk production and content remains to be established. However, studies have established a linear relationship between milk folate concentration and soluble folate binding protein (FBP), currently known as soluble folate receptor (FR) [81]. It should be noted that the transport of folate from the plasma to the milk occurs

against a steep concentration gradient (up to 14-fold); therefore, it has been originally proposed that this FBP, which is abundant in human milk, plays a role in folate trapping for secretion into the milk [81]. Although the significance of FBP in milk is not fully revealed, cumulative evidence supports the notion that it is essential for folate secretion, possibly via exocytosis, as occurring with various milk proteins [82]. The presence of folate as a high affinity ($K_d = 10^{-9} - 10^{-10}$ M) bound species to FBP certainly stabilizes folate, prevents its accessibility to metabolic enzymes, and may enhance its bioavailability to infants [82]. Indeed, original *in vivo* studies have shown that, in contrast to free folic acid, the complex folic acid–FBP was avidly absorbed in the ileum, suggesting a mechanism of intestinal absorption that is distinct from the canonical intestinal folate absorption mediated by the proton-coupled folate transporter (PCFT/SLC46A1) [83,84].

Regarding folate concentration in human milk, in a Canadian cohort study, five folate-related SNPs—*MTHFR* 677C > T (rs1801133), *MTHR* 1298A > C (rs1801131), *MTHFR* 1793G > A (rs2274976), *MTR* 2756A > G (rs1805087), and *MTRR* 66A > G (rs1801394)—were examined for their effect on folate concentration in mother's milk [85]. None of these SNPs were associated with total folate concentration, however, the *MTHFR* 677C > T SNP was associated with higher levels of unmetabolized folic acid in human milk [85].

3.6. Fat Percentage in Human Milk

Milk fat is the major energy source in the infant's diet [86,87]. Human milk fat composition displays large inter- and intra-individual variation among lactating mothers depending on the duration of lactation, the time during the day, as well as each breastfeeding [88]. However, to the best of our knowledge, genetic variations that affect human milk fat content were not reported to date. In contrast, owing to the high economic importance of fat contents in dairy products, this topic was characterized in depth in dairy animals [12,89–95]. The diacylglycerol o-acyltransferase 1 (*DGAT1*) gene encodes for one of the enzymes that covalently attaches diacylglycerol to long-chain fatty acyl-CoAs to form triglycerides [96], which are the major fat type present in milk. Genetic variations in *DGAT1* were highly associated with fat content in dairy animals [89,96–103]. Additionally, these alterations were also associated with milk protein content and milk volume in some species [98,99]. In humans, homozygous recessive mutations in *DGAT1* were found to cause severe congenital diarrhea and protein-losing enteropathy in infants shortly after birth [104,105]. However, the effect of heterozygous mutations on human health and more specifically on human milk production was not yet characterized.

3.7. Fatty Acid Desaturases (*FADS*) and Fatty Acid Composition in Human Milk

FADS1 and *FADS2* encode for fatty acid desaturases (FADS), which are involved in the biosynthesis of docosahexanoic acid (DHA) from α -linolenic acid. Fish and fish oil in the diet are good sources of DHA [23]. Human milk fatty acids were shown to be influenced by the genotype of the *FADS1* and *FADS2* gene cluster, with significantly lower 14:0, arachidonic acid (ARA), and eicosapentanoic acid (EPA), but higher 20:2 in the minor allele homozygotes of rs174553 (GG), rs99780 (TT), and rs174583 (TT). In contrast, lower ARA, EPA, 22:5, and DHA were found in women carrying the minor homozygous allele G/G of rs174575 [66]. Furthermore, a cohort study ($n = 309$) that examined the effect of three different SNPs in *FADS1* and *FADS2* (*FADS1* rs174561, *FADS2* rs174575, and intergenic rs3834458) on DHA levels in plasma and breast milk I (one month after birth) found lower proportions of DHA in milk from women who were homozygous for the minor allele. This lower proportion could not be compensated for by dietary fish consumption [23]. These findings were later supported by other studies that found that SNPs in the FADS gene cluster influence polyunsaturated fatty acid (PUFA) concentrations in human milk [106–108]. Together with a recently published study that found that mothers carrying the minor allele of *FADS1* rs174556 had lower proportions of ARA [108], this finding strongly indicated that genetic variations affect human milk composition. Additionally, genetic variations in FADS and elongase (*ELOVL*) enzymes were shown to affect long chain PUFA (LC-PUFA) levels in human colostrum. Importantly, these variations and human milk LC-PUFA concentration were associated with an advantage in the child's cognitive

ability at the age of 14 months [109]. These findings were later supported by a study on Chinese women that showed correlation between different SNPs in *ELOVL2* and *ELOVL5* and LC-PUFA concentrations [110]. Interestingly, this study found that certain SNP haplotypes together with high dietary intake of DHA increased PUFA levels in human milk when compared with other haplotypes [110]. Higher concentrations of n – 3 long-chain polyunsaturated fatty acids (LCPs), as well as ruminant fatty acids in human milk, showed a protective role in the development of atopic dermatitis (eczema) [111]. These findings highlight the importance of further characterization of genetic variations that affect human milk fatty acid composition that may affect the infant's nutritional status. These variations may have a long-term effect on the cognition and development of these infants. In these cases, nutrient supplementation of the infant diet may be a possible treatment to enhance infant's health and cognition.

3.8. Human Milk Protein Content

SNPs were suggested to contribute to the normal variations in human milk protein composition [112]. This phenomenon was better characterized in dairy animals, where SNPs in the bovine casein locus were found to be associated with milk yield and milk protein concentration [113,114]; however, very little is known about nucleotide variation and protein content in humans. SNPs in α -lactalbumin were found and characterized in a population containing different ethnic groups, in which no effect was observed on milk α -lactalbumin or lactose concentrations [112]. Further research is needed in order to determine if maternal genetic variations in genes such as casein have an influence on human milk protein content.

3.9. Human Milk Oligosaccharides (HMOs)

HMOs, a structurally complex and diverse group of glycans, represent the third most abundant component in human milk right after lactose and lipids (excluding water) [115]. HMOs are thought to participate in numerous functions including metabolism, probiotic and prebiotic, antimicrobial, modulation of infant intestinal epithelial cell responses, immune response, nutritional effects, as well as brain development [70,115–119]. Like blood groups, the composition of HMOs depends on the expression of certain glycosyltransferases. On the basis of the secretor (Se) and Le blood group system, which is determined by the activity of two gene loci encoding for the α 1-2-fucosyltransferase FUT2 (encoded by the Se gene) and the α 1-3/4-fucosyltransferase FUT3 (encoded by the Le gene), four milk groups were assigned: Le-positive secretors (Se^+Le^+), Le-negative secretors (Se^+Le^-), Le-positive non-secretors (Se^-Le^+), and Le-negative non-secretors (Se^-Le^-) [116]. Significant differences in the abundance of total as well as fucosylated HMOs were found in a study that compared the content of HMOs of secretor and non-secretor Chinese mothers [119]. Additionally, the nonsense mutation W143X that introduces a premature stop codon in the fucosyltransferase-2 (FUT2) gene (rs601338), abolished its ability to synthesize α (1-2)-fucosylated HMOs and affected the composition of the bifidobacterial population in the infant's gut [115,120]. In a cohort study that examined HMO levels in Malawian mothers, the total and fucosylated HMO content of milk samples collected from secretor mothers was significantly higher than that of non-secretors [70]. Additionally, two cohorts on Malawian mothers found higher levels of HMOs in the milk of mothers of healthy infants, compared with stunted infants, and these differences were even greater in the group of non-secretor mothers [70]. These findings suggest that HMOs play an important role in infant growth, specifically in undernourished populations. This study highlights the importance of considering the mother's genetic background in evaluating milk HMOs' composition. In addition, fucosylated oligosaccharides in the mother's milk, which depend on the mother's secretor status, were shown to be highly correlated with the infant gut microbiota diversity and function [71,121–123]. The percentage of secretor and non-secretor status in the population may vary widely in different ethnic groups. For example, European and American populations have a non-secretor frequency of approximately 20%, whereas higher frequencies of 32%–38% were found in West African populations [124]. The Canadian Healthy Infant Longitudinal Development (CHILD) cohort study, which enrolled 3624 pregnant mothers from the general population in four major cities across Canada,

found that 40% of the Asian population, and 26% of the Caucasian population were non-secretor mothers [125]. Taking into consideration the large number of papers showing a beneficial effect of HMOs on infant growth and development, the genetic variations in different ethnic groups may have a great impact on infant growth, through differential HMOs' abundance, and further studies in this important domain are warranted.

3.10. Other Genes

Cui et al., performed RNA-seq analysis on mammary gland samples from Holstein cows with extremely high and low protein and fat percentage. Using this high throughput analysis, they identified 31 differentially expressed genes, the expression levels of which were associated with the milk content in these cows [126]. After comparing their data with the genome-wide association study (GWAS) results, they were able to narrow the list of genes to seven candidates that mostly affected milk fat and protein content (*TRIB3*, *SAA1*, *SAA3*, *M-SAA3.2*, *VEGFA*, *PTHLH*, and *RPL23A*). These genes were shown to play a role in lipid metabolism (*TRIB3* and *SAA*), secretory functions in the mammary gland (*VEGFA*), as well as mammary gland development (*PTHLH*) [126]. Thus, it will be highly important to test the effect of genetic variations in these genes on human milk composition.

4. Genetic Variations that Affect Human Milk Supply

4.1. Prolactin

A few cases of familial alactogenesis were reported in the literature [127–130] as a result of various etiologies. One case with a genetic etiology was identified in a woman carrying a single point mutation in the prolactin gene (*PRL*). This mutation (c.658C > T) was reported to result a premature translation termination, which leads to a marked decrease in the mRNA of this gene via nonsense-mediated RNA decay, hence resulting in familial alactogenesis [131]. The identified LoF mutation in *PRL* was also associated with infertility in this family [131], indicating that women suffering from infertility are more prone to suffer from breastfeeding difficulties and should receive more attention and support in order to succeed in breastfeeding. However, in another case of familial alactogenesis, no mutation in *PRL* was found, indicating that variations in other genes may be associated with alactogenesis. In yet another case, an autoimmune etiology was suggested to cause an isolated *PRL* deficiency and puerperal alactogenesis in women [129]. These cases emphasize the importance of identifying genetic variations that affect human milk production in order to improve physician diagnosis and reduce women's stress from breastfeeding failure.

4.2. Prolactin Receptor (*PRLR*)

The prolactin receptor (*PRLR*) was found to be widely associated with milk yield in dairy animals [132–134]. Additionally, *prlr*^{+/-} mouse dams showed lactation problems and *prlr* knockout mouse dams failed to display lobuloalveolar development [135]. In humans, a heterozygous LoF mutation (p.His188Arg) in *PRLR* was reported in three sisters with familial hyperprolactinemia [136]. Hyperprolactinemia is determined by higher than normal range levels of prolactin, in which 50% of the cases are caused by tumors [137]. In this case, two sisters suffered from oligomenorrhea and infertility and one sister, between 18 and 31 years of age, had four successful pregnancies with lactation and was treated with dopamine agonist therapy to terminate persistent galactorrhea [136]. The late onset of post-pubertal hyperprolactinemia may explain the differences in the phenotypes between these sisters [136]. However, the fact that one of these sisters, who was successful in lactating her infants, was heterozygous for an LoF mutation in *PRLR* reveals that the latter mutation did not necessarily inhibit or abrogate lactation outcomes. The effect of LoF mutations in *PRLR* on galactorrhea after lactation should be further investigated.

Another case of compound LoF mutations (nonsense R171Ter) and missense (P269L) mutations in the human *PRLR* was recently reported [138]. In this case, the proband's mother and father were heterozygous for the R171Ter and P269L mutations. The proband suffered from hyperprolactinemia associated with postpartum agalactia, and the mother who carried the heterozygous R171Ter

mutation reported insufficient human milk production after her pregnancies, but was successful in breastfeeding when combined with the addition of baby formula until three months post-partum [138]. These findings strongly suggest that homozygous LoF mutations or heterozygous mutations in *RPLR* may have a prominent influence on lactation outcomes and that the prevalence of such mutations in the population should be examined for early diagnosis and support of women that carry these mutations during breastfeeding.

5. Discussion

Evolutionary Explanation for Genetic Variation that Affects Human Milk Composition

The ectodysplasin A receptor (EDAR) is responsible for mammary gland ductal branching as well as inducing sweat gland density and incisor shoveling [139]. The EDAR V370A isoform is highly elevated in the North and East Asian populations. It was recently suggested to be a result of positive selection of this allele to increase ductal branching in the mammary gland, thereby enhancing the transfer of critical nutrients to infants through the breast milk during the Last Glacial Maximum [139]. The author suggested that during the Last Glacial Maximum (LGM; 28,000–18,000 years ago), people were living in Arctic Beringia and were exposed to very low levels of UV radiation, which can lead to dangerously low levels of biosynthesized vitamin D [139]. These people experienced selection for polymorphisms in the FADS gene cluster (the encoded enzymes of which are responsible for long fatty acids composition in breast milk) and for *EDAR V370A* because of the advantage of these genetic variants in conferring a better transmission of nutrients from mother to infant through breast milk under conditions of extremely low UV [139].

Another clue for genetic influence on human milk stems from a study that compared the onset of lactogenesis and volume of milk output until the fifth post-delivery day in four ethnic groups: Arabs, Africans, Eastern Europeans, and Italians [140]. The earliest onset of lactation and the highest milk output was registered among Arab and Eastern European women, and they concluded that ethnicity is associated with breastfeeding characterization [140]. These differences between the different ethnic groups may also be related to genetic variations in these populations that evolved under certain environmental conditions in history. One example for such unique ethnic-related SNP is rs35235055 (c.68T > C causing L23P) SNP in *SLC30A2/ZnT2*, which is highly frequent in Africans. As mentioned above, this SNP was associated with low levels of zinc in human milk [37,141], and it will be interesting to explore if this SNP had some evolutionary advantage in this specific ethnic group.

In addition to variations in *FUT2* and *FUT3* that were detected at different frequencies in different ethnic groups, as mentioned in Section 3.9 above, other nutrient-related genes were found to be more abundant in some ethnic groups. One example concerns variations in FADS genes, in which approximately 80% of African Americans carry two copies of the G allele at rs174537, which is associated with increased levels of ARA, compared with only 45% of European Americans [142]. These variations may affect individuals' risk for inflammatory diseases as well as alter their response to dietary interventions [142]. These variations should be taken into consideration upon dietary recommendations setting as well as in breastfeeding and human milk studies. These findings highlight the importance of evaluating genetic variations that are more frequent in specific ethnic groups and offer specific nutritional recommendations based on the identification of genetic variations.

6. Conclusions

Mammalian breast milk has evolved over millions of years to optimally supply all the necessary nutrients that infants need in order to grow in their first months of life (Figure 1). Production of nutrient-deficient breast milk is against the evolutionary selection, thus genetic variations that diminish breast milk quantity (i.e., volume) and quality (i.e., composition) are relatively rare. However, owing to the use of wet nursing and baby formula, the cases of women who produce nutrient-deficient human milk or who struggle with breastfeeding because of low milk supply, could

have been masked. Therefore, genetic variations that affect human milk production, without affecting other physiological functions, may emerge in the population. Furthermore, some of the genetic variations that were discussed above are also associated with infertility. Nowadays, when medical interventions like artificial insemination and *in vitro* fertilization are routinely available, increased attention should be given to the effect of infertility on breastfeeding, and to support these mothers during breastfeeding if needed.

Nutrigenetics and nutrigenomics have been receiving increasing attention over the years, and genetics-based diets are already used [143,144]. Additionally, genetic testing is widely applied for identification of heritable diseases before and during pregnancy [10]. Breast milk is the optimal nutrition for infants in the vast majority of cases; however, in some cases as we described in this article, genetic variations may lead to deleterious changes in milk composition or volume. Maternal genetic tests for candidate genes, some of which were discussed above, and additional genes that will be identified in the future, which may regulate human milk production and composition, may improve maternal and infant health. In cases of nutrient deficiencies like in the case of LoF mutations in *SLC30A2/ZnT2*, which lead to production of zinc-deficient human milk, supplementation of nutrients directly to the infant together with continuing breastfeeding can prevent the disease and improve infant health (Figure 1). In cases of low human milk production, mothers may completely give up on breastfeeding owing to low supply and relatively slow weight gain of the infant. In these cases, mothers that tend to breastfeed and did not reach their own goals may experience failure and depression feelings [10]. However, if the underlying genetic basis could be identified for low milk supply, these women could obtain proper medical attention and support for breastfeeding, and hence continue breastfeeding as long as possible, with less guilt feelings and less stress owing to low milk production. In the future, gene therapy to support breastfeeding may be another option to overcome breastfeeding difficulties.

Personalized medicine implies that the treatment or the drug that is administered to an individual patient should be prescribed based on specific tests or molecular analysis; therefore, the drug should better fit the patient's disease and lead to improved treatment [145]. One example is drugs that are prescribed based on the patient's DNA sequence. In recent years, expression of genes such as estrogen receptor (ER) and HER2 has frequently been tested in breast cancer in order to achieve targeted precision medicine [146]. Nowadays, high-throughput technologies such as next generation sequencing (NGS) are used in research and lead to the finding of a high number of heterogeneous gain or loss of function mutations in cancer specimens [146]. However, to translate these research findings into the clinical arena might be challenging and also very expensive, and thus may take a long time to implement [145].

Personalized nutrition (or precision nutrition, nutrigenomics, nutrigenetics, and nutritional genomics) is based on the same principles of personalized medicine, but the treatment is based on the human nutrition instead of drugs or medical treatments [147,148]. Personalized nutrition was recently shown to be very effective in controlling postprandial blood glucose levels [149]. In this study, the researchers developed an algorithm that can predict the postprandial blood glucose levels based on the patient's microbiome, blood parameters, dietary habits, anthropometrics, and physical activity [149]. In addition, using this algorithm, they were able to successfully generate personalized nutritional recommendation that could lower the postprandial blood glucose levels of the subjects [149]. Other studies used genetics-based analysis, for example, the apoE [150] or amylase [151] genes, to obtain better personalized nutritional recommendation.

Breast milk is the natural version of personalized nutrition. Mothers producing the best food for their infants and milk composition may vary depending on the infants age [19], gender [152], health status [153], and more. In the future, when we will have better insight into the genes that regulate human milk content, we will be able to predict which specific component might be deficient in a certain lactating mother or specific ethnic group, owing to genetic variation/alterations, as we mentioned in this review, and to supplement the infants or the mother diet if needed. These genetic tests will support infant health, growth, and development. Additionally, genetic testing that could determine if the mother is carrying a variation in a gene that may lead to low milk supply could give

the medical team an indication that the mother needs more support in order to succeed in achieving her goals of breastfeeding. Furthermore, these tests could reduce mothers' stress and failure feelings when facing breastfeeding difficulties owing to genetic alterations.

In summary, we herein discussed several deleterious genetic alterations that may lead to significant effects on human milk composition or human milk supply. Further research is warranted in order to identify other genes that regulate human milk production and composition, as well as cellular pathways that are responsible for nutrient transport into human milk. In addition, genetic variations in these genes that affect human milk composition and supply should be further characterized towards the improvement of the health of both the infant and mother.




Figure 1. Schematic illustration of the mechanism of transport of micronutrients in human lactocytes during lactation. ATP-driven, multidrug efflux transporter (ABCG2) [38,154], NIS [51,61], and ZnT2 transporter [21,155] were shown to transport riboflavin (vitamin B2), iodine, and zinc, respectively, in human mammary gland epithelial cells during lactation. The anion transporter TMEM16A is predicted to transport iodine into human milk [47,48].

Author Contributions: Y.G. and Y.G.A. performed the literature search and data analysis; Y.G. wrote the first draft; and Y.G.A. critically revised the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This review paper received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Fu, N.Y.; Nolan, E.; Lindeman, G.J.; Visvader, J.E. Stem Cells and the Differentiation Hierarchy in Mammary Gland Development. *Physiol. Rev.* **2020**, *100*, 489–523, doi:10.1152/physrev.00040.2018.
2. Pal, P.; Sahu, J.; Grewal, S.; Aggarwal, A.; Ghosh, S. Role of hormones in persistency of lactation: A review. *J. Entomol. Zool. Stud.* **2019**, *7*, 677–686.
3. Wang, Q.A.; Scherer, P.E. Remodeling of Murine Mammary Adipose Tissue during Pregnancy, Lactation, and Involution. *J. Mammary Gland Biol. Neoplasia* **2019**, *24*, 207–212.
4. Neville, M.C.; Anderson, S.M.; McManaman, J.L.; Badger, T.M.; Bunik, M.; Contractor, N.; Crume, T.; Dabelea, D.; Donovan, S.M.; Forman, N.; et al. Lactation and Neonatal Nutrition: Defining and Refining the Critical Questions. *J. Mammary Gland Biol. Neoplasia* **2012**, *17*, 167–188, doi:10.1007/s10911-012-9261-5.
5. Truchet, S.; Honvo-Houéto, E. Physiology of milk secretion. *Best Pract. Res. Clin. Endocrinol. Metab.* **2017**, *31*, 367–384.
6. Pang, W.W.; Hartmann, P.E. Initiation of Human Lactation: Secretory Differentiation and Secretory Activation. *J. Mammary Gland Biol. Neoplasia* **2007**, *12*, 211–221, doi:10.1007/s10911-007-9054-4.
7. Crowley, W.R. Neuroendocrine regulation of lactation and milk production. *Compr. Physiol.* **2015**, *5*, 255–291, doi:10.1002/cphy.c140029.
8. Leng, G.; Caquineau, C.; Sabatier, N. Regulation of Oxytocin Secretion. *Vitam. Horm.* **2005**, *71*, 27–58.

9. Feldman, R.; Bakermans-Kranenburg, M.J. Oxytocin: A parenting hormone. *Curr. Opin. Psychol.* **2017**, *15*, 13–18.
10. Guttmacher, A.E.; Collins, F.S.; Burke, W. Genomic medicine: Genetic testing. *N. Engl. J. Med.* **2002**, *347*, 1867–1875.
11. Bardanzellu, F.; Fanos, V.; Reali, A. “Omics” in Human Colostrum and Mature Milk: Looking to Old Data with New Eyes. *Nutrients* **2017**, *9*, 843, doi:10.3390/nu9080843.
12. Martin, P.; Palhière, I.; Maroteau, C.; Bardou, P.; Canale-Tabet, K.; Sarry, J.; Woloszyn, F.; Bertrand-Michel, J.; Racke, I.; Besir, H.; et al. A genome scan for milk production traits in dairy goats reveals two new mutations in Dgat1 reducing milk fat content. *Sci. Rep.* **2017**, *7*, doi:10.1038/s41598-017-02052-0.
13. Klein, L.D.; Breakey, A.A.; Scelza, B.; Vallenggia, C.; Jasienska, G.; Hinde, K. Concentrations of trace elements in human milk: Comparisons among women in Argentina, Namibia, Poland, and the United States. *PLoS ONE* **2017**, *12*, e0183367, doi:10.1371/journal.pone.0183367.
14. Bravi, F.; Wiens, F.; Decarli, A.; Dal Pont, A.; Agostoni, C.; Ferraroni, M. Impact of maternal nutrition on breast-milk composition: A systematic review. *Am. J. Clin. Nutr.* **2016**, *104*, 646–662.
15. Keikha, M.; Bahreynian, M.; Saleki, M.; Kelishadi, R. Macro- and Micronutrients of Human Milk Composition: Are They Related to Maternal Diet? A Comprehensive Systematic Review. *Breastfeed. Med.* **2017**, *12*, 517–527, doi:10.1089/bfm.2017.0048.
16. Daniels, L.; Gibson, R.S.; Diana, A.; Haszard, J.J.; Rahmanna, S.; Luftimas, D.E.; Hampel, D.; Shahab-Ferdows, S.; Reid, M.; Melo, L.; et al. Micronutrient intakes of lactating mothers and their association with breast milk concentrations and micronutrient adequacy of exclusively breastfed Indonesian infants. *Am. J. Clin. Nutr.* **2019**, *110*, 391–400, doi:10.1093/ajcn/nqz047.
17. Specker, B.L.; Black, A.; Allen, L.; Morrow, F. Vitamin B-12: Low milk concentrations are related to low serum concentrations in vegetarian women and to methylmalonic aciduria in their infants1-3. *Am. J. Clin. Nutr.* **1990**, *52*, 1073–1076, doi:10.1093/ajcn/52.6.1073.
18. Valentine, C.J.; Wagner, C.L. Nutritional Management of the Breastfeeding Dyad. *Pediatr. Clin. N. Am.* **2013**, *60*, 261–274.
19. Dror, D.K.; Allen, L.H. Overview of nutrients in humanmilk. *Adv. Nutr.* **2018**, *9*, 278S–294S, doi:10.1093/advances/nmy022.
20. Hampel, D.; Dror, D.K.; Allen, L.H. Micronutrients in Human Milk: Analytical Methods. *Adv. Nutr.* **2018**, *9*, 313S–331S, doi:10.1093/advances/nmy017.
21. Golan, Y.; Kambe, T.; Assaraf, Y.G. The role of the zinc transporter SLC30A2/ZnT2 in transient neonatal zinc deficiency. *Metallomics* **2017**, *9*, 1352–1366, doi:10.1039/c7mt00162b.
22. Fischer, L.M.; da Costa, K.A.; Galanko, J.; Sha, W.; Stephenson, B.; Vick, J.; Zeisel, S.H. Choline intake and genetic polymorphisms influence choline metabolite concentrations in human breast milk and plasma. *Am. J. Clin. Nutr.* **2010**, *92*, 336–346, doi:10.3945/ajcn.2010.29459.
23. Moltó-Puigmartí, C.; Plat, J.; Mensink, R.P.; Müller, A.; Jansen, E.; Zeegers, M.P.; Thijs, C. FADS1 FADS2 gene variants modify the association between fish intake and the docosahexaenoic acid proportions in human milk. *Am. J. Clin. Nutr.* **2010**, *91*, 1368–1376, doi:10.3945/ajcn.2009.28789.
24. Chowanadisai, W.; Lönnerdal, B.; Kelleher, S.L. Identification of a mutation in SLC30A2 (ZnT-2) in women with low milk zinc concentration that results in transient neonatal zinc deficiency. *J. Biol. Chem.* **2006**, doi:10.1074/jbc.M605821200.
25. Castillo, S.; Juan, S. Zinc Transporter SLC30A2 Genetic Variations and Health Implications. Master’s Thesis, University of Manitobain, Canada, 2014.
26. Isumura, N.; Kibihara, Y.; Fukue, K.; Miyata, A.; Fukushima, K.; Tamagawa-Mineoka, R.; Katoh, N.; Nishito, Y.; Ishida, R.; Narita, H.; et al. Novel mutations in SLC30A2 involved in the pathogenesis of transient neonatal zinc deficiency. *Pediatr. Res.* **2016**, *80*, 586–594, doi:10.1038/pr.2016.108.
27. Miletta, M.C.; Bieri, A.; Kernland, K.; Schöni, M.H.; Petkovic, V.; Flück, C.E.; Eblé, A.; Mullis, P.E. Transient Neonatal Zinc Deficiency Caused by a Heterozygous G87R Mutation in the Zinc Transporter ZnT-2 (SLC30A2) Gene in the Mother Highlighting the Importance of Zn²⁺ for Normal Growth and Development. *Int. J. Endocrinol.* **2013**, *2013*, 259189, doi:10.1155/2013/259189.
28. Liew, H.M.; Tan, C.W.; Ho, C.K.M.; Chee, J.N.; Koh, M.J.A. Transient Neonatal Zinc Deficiency Caused by a Novel Mutation in the SLC30A2 Gene. *Pediatr. Dermatol.* **2017**, *1–2*, doi:10.1111/pde.13065.
29. Lasry, I.; Seo, Y.A.; Ityel, H.; Shalva, N.; Pode-Shakked, B.; Glaser, F.; Berman, B.; Berezovsky, I.; Goncarenco, A.; Klar, A.; et al. A dominant negative heterozygous G87R mutation in the zinc transporter,

- ZnT-2 (SLC30A2), results in transient neonatal zinc deficiency. *J. Biol. Chem.* **2012**, *287*, 29348–29361, doi:10.1074/jbc.M112.368159.
30. Lova Navarro, M.; Vera Casano, A.; Benito Lopez, C.; Fernandez Ballesteros, M.D.; Godoy Diaz, D.J.; Crespo Erchiga, A.; Romero Brufau, S. Transient neonatal zinc deficiency due to a new autosomal dominant mutation in gene SLC30A2 (ZnT-2). *Pediatr. Dermatol.* **2014**, *31*, 251–252, doi:10.1111/pde.12257.
 31. Golan, Y.; Itsumura, N.; Glaser, F.; Berman, B.; Kambe, T.; Assaraf, Y.G. Molecular Basis of Transient Neonatal Zinc Deficiency: NOVEL ZnT2 MUTATIONS DISRUPTING ZINC BINDING AND PERMEATION. *J. Biol. Chem.* **2016**, *291*, 13546–13559, doi:10.1074/jbc.M116.732693.
 32. Golan, Y.; Yerushalmi, B.; Efrati, E.; Assaraf, Y.G. Identification of Genetic Diseases Using Breast Milk Cell Analysis: The Case of Transient Neonatal Zinc Deficiency (TNZD). *Cell. Mol. Med.* **2017**, *3*, doi:10.21767/2573-5365.100031.
 33. Itsumura, N.; Inamo, Y.; Okazaki, F.; Teranishi, F.; Narita, H.; Kambe, T.; Kodama, H. Compound heterozygous mutations in SLC30A2/ZnT2 results in low milk zinc concentrations: A novel mechanism for zinc deficiency in a breast-fed infant. *PLoS ONE* **2013**, *8*, e64045, doi:10.1371/journal.pone.0064045.
 34. Golan, Y.; Lehy, A.; Horev, G.; Assaraf, Y.G. High proportion of transient neonatal zinc deficiency causing alleles in the general population. *J. Cell. Mol. Med.* **2018**, *23*, doi:10.1111/jcmm.13982.
 35. Lasry, I.; Golan, Y.; Berman, B.; Amram, N.; Glaser, F.; Assaraf, Y.G. In situ dimerization of multiple wild type and mutant zinc transporters in live cells using bimolecular fluorescence complementation. *J. Biol. Chem.* **2014**, *289*, 7275–7292, doi:10.1074/jbc.M113.533786.
 36. Lee, S.; Hennigar, S.R.; Alam, S.; Nishida, K.; Kelleher, S.L. Essential Role for Zinc Transporter 2 (ZnT2)-mediated Zinc Transport in Mammary Gland Development and Function during Lactation. *J. Biol. Chem.* **2015**, *290*, 13064–13078, doi:10.1074/jbc.M115.637439.
 37. Qian, L.; Wang, B.; Tang, N.; Zhang, W.; Cai, W. Polymorphisms of SLC30A2 and selected perinatal factors associated with low milk zinc in Chinese breastfeeding women. *Early Hum. Dev.* **2012**, *88*, 663–668, doi:10.1016/j.earlhumdev.2012.01.011.
 38. van Herwaarden, A.E.; Wagenaar, E.; Merino, G.; Jonker, J.W.; Rosing, H.; Beijnen, J.H.; Schinkel, A.H. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. *Mol. Cell. Biol.* **2007**, *27*, 1247–1253, doi:10.1128/MCB.01621-06.
 39. Yue, W.; Fang, X.; Zhang, C.; Pang, Y.; Xu, H.; Gu, C.; Shao, R.; Lei, C.; Chen, H. Two novel SNPs of the ABCG2 gene and its associations with milk traits in Chinese Holsteins. *Mol. Biol. Rep.* **2011**, *38*, 2927–2932, doi:10.1007/s11033-010-9955-y.
 40. Cohen-Zinder, M.; Seroussi, E.; Larkin, D.M.; Loo, J.J.; Everts-Van Der Wind, A.; Lee, J.H.; Drackley, J.K.; Band, M.R.; Hernandez, A.G.; Shani, M.; et al. Identification of a missense mutation in the bovine ABCG2 gene with a major effect on the QTL on chromosome 6 affecting milk yield and composition in Holstein cattle. *Genome Res.* **2005**, *15*, 936–944, doi:10.1101/gr.3806705.
 41. Malfará, B.N.; Benzi, J.R. de L.; de Oliveira Filgueira, G.C.; Zanelli, C.F.; Duarte, G.; de Carvalho Cavalli, R.; de Moraes, N.V. ABCG2 c.421C>A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women. *Reprod. Toxicol.* **2019**, *85*, 1–5, doi:10.1016/j.reprotox.2019.01.007.
 42. Dror, D.K.; Allen, L.H. Iodine in Human Milk: A Systematic Review. *Adv. Nutr.* **2018**, *9*, 347S–357S, doi:10.1093/advances/nmy020.
 43. Wirth, E.K.; Meyer, F. Neuronal effects of thyroid hormone metabolites. *Mol. Cell. Endocrinol.* **2017**, *458*, 136–142, doi:10.1016/j.mce.2017.01.007.
 44. Horn, S.; Heuer, H. Thyroid hormone action during brain development: More questions than answers. *Mol. Cell. Endocrinol.* **2010**, *315*, 19–26.
 45. Bernal, J. Thyroid Hormones and Brain Development. *Vitam. Horm.* **2005**, *71*, 95–122.
 46. Semba, R.D.; Delange, F. Iodine in Human Milk: Perspectives for Infant Health. *Nutr. Rev.* **2009**, *59*, 269–278, doi:10.1111/j.1753-4887.2001.tb05512.x.
 47. Kamikawa, A.; Ichii, O.; Sakazaki, J.; Ishikawa, T. Ca²⁺-activated Cl⁻ channel currents in mammary secretory cells from lactating mouse. *Am. J. Physiol. Physiol.* **2016**, *311*, C808–C819, doi:10.1152/ajpcell.00050.2016.
 48. De La Vieja, A.; Santisteban, P. Role of iodide metabolism in physiology and cancer. *Endocr. Relat. Cancer* **2018**, *25*, R225–R245, doi:10.1530/ERC-17-0515.

49. Lemay, D.G.; Ballard, O.A.; Hughes, M.A.; Morrow, A.L.; Horseman, N.D.; Nommsen-Rivers, L.A. RNA Sequencing of the Human Milk Fat Layer Transcriptome Reveals Distinct Gene Expression Profiles at Three Stages of Lactation. *PLoS ONE* **2013**, *8*, doi:10.1371/journal.pone.0067531.
50. Tazebay, U.H.; Wapnir, I.L.; Levy, O.; Dohan, O.; Zuckier, L.S.; Zhao, Q.H.; Deng, H.F.; Amenta, P.S.; Fineberg, S.; Pestell, R.G.; et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. *Nat. Med.* **2000**, *6*, 871–878, doi:10.1038/78630.
51. Ravera, S.; Reyna-Neyra, A.; Ferrandino, G.; Amzel, L.M.; Carrasco, N. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. *Annu. Rev. Physiol.* **2017**, *79*, 261–289, doi:10.1146/annurev-physiol-022516-034125.
52. Nicola, J.P.; Nazar, M.; Serrano-Nascimento, C.; Goulart-Silva, F.; Sobrero, G.; Testa, G.; Nunes, M.T.; Muñoz, L.; Miras, M.; Masini-Repiso, A.M. Iodide transport defect: Functional characterization of a novel mutation in the Na⁺/I⁻ symporter 5'-untranslated region in a patient with congenital hypothyroidism. *J. Clin. Endocrinol. Metab.* **2011**, *96*, E1100–E1107, doi:10.1210/jc.2011-0349.
53. Mizokami, T.; Fukata, S.; Hishinuma, A.; Kogai, T.; Hamada, K.; Maruta, T.; Higashi, K.; Tajiri, J. Iodide Transport Defect and Breast Milk Iodine. *Eur. Thyroid J.* **2016**, *5*, 145–148, doi:10.1159/000446496.
54. Reed-Tsur, M.D.; De La Vieja, A.; Ginter, C.S.; Carrasco, N. Molecular characterization of V59E NIS, a Na⁺/I⁻ symporter mutant that causes congenital I⁻ transport defect. *Endocrinology* **2008**, *149*, 3077–3084, doi:10.1210/en.2008-0027.
55. Paroder, V.; Nicola, J.P.; Ginter, C.S.; Carrasco, N. The iodide-transport-defect-causing mutation R124H: A δ-amino group at position 124 is critical for maturation and trafficking of the Na⁺/I⁻ symporter. *J. Cell Sci.* **2013**, *126*, 3305–3313, doi:10.1242/jcs.120246.
56. Kosugi, S.; Okamoto, H.; Tamada, A.; Sanchez-Franco, F. A novel peculiar mutation in the sodium/iodide symporter gene in Spanish siblings with iodide transport defect. *J. Clin. Endocrinol. Metab.* **2002**, *87*, 3830–3836, doi:10.1210/jcem.87.8.8767.
57. De la Vieja, A.; Ginter, C.S.; Carrasco, N. The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number. *J. Cell Sci.* **2004**, *117*, 677–687, doi:10.1242/jcs.00898.
58. Nicola, J.P.; Reyna-Neyra, A.; Saenger, P.; Rodriguez-Buritica, D.F.; Godoy, J.D.G.; Muzumdar, R.; Amzel, L.M.; Carrasco, N. Sodium/iodide symporter mutant V270E causes stunted growth but no cognitive deficiency. *J. Clin. Endocrinol. Metab.* **2015**, *100*, E1353–E1361, doi:10.1210/jc.2015-1824.
59. Pohlenz, J.; Medeiros-Neto, G.; Gross, J.L.; Silveiro, S.P.; Knobel, M.; Refetoff, S. Hypothyroidism in a Brazilian kindred due to iodide trapping defect caused by a homozygous mutation in the sodium/iodide symporter gene. *Biochem. Biophys. Res. Commun.* **1997**, *240*, 488–491, doi:10.1006/bbrc.1997.7594.
60. Montanelli, L.; Agretti, P.; De Marco, G.; Bagattini, B.; Ceccarelli, C.; Brozzi, F.; Lettierio, T.; Cerbone, M.; Vitti, P.; Salerno, M.; et al. Congenital hypothyroidism and late-onset goiter: Identification and characterization of a novel mutation in the sodium/iodide symporter of the proband and family members. *Thyroid* **2009**, *19*, 1419–1425, doi:10.1089/thy.2009.0080.
61. Levy, O.; Ginter, C.S.; De la Vieja, A.; Levy, D.; Carrasco, N. Identification of a structural requirement for thyroid Na⁺/I⁻ symporter (NIS) function from analysis of a mutation that causes human congenital hypothyroidism. *FEBS Lett.* **1998**, *429*, 36–40, doi:10.1016/S0014-5793(98)00522-5.
62. Dohán, O.; Verónica Gavrielides, M.; Ginter, C.; Mario Amzel, L.; Carrasco, N. Na⁺/I⁻ symporter activity requires a small and uncharged amino acid residue at position 395. *Mol. Endocrinol.* **2002**, *16*, 1893–1902, doi:10.1210/me.2002-0071.
63. Li, W.; Nicola, J.P.; Amzel, L.M.; Carrasco, N. Asn441 plays a key role in folding and function of the Na⁺/I⁻ symporter (NIS). *FASEB J.* **2013**, *27*, 3229–3238, doi:10.1096/fj.13-229138.
64. De La Vieja, A.; Ginter, C.S.; Carrasco, N. Molecular analysis of a congenital iodide transport defect: G543E impairs maturation and trafficking of the Na⁺/I⁻ symporter. *Mol. Endocrinol.* **2005**, *19*, 2847–2858, doi:10.1210/me.2005-0162.
65. Pohlenz, J.; Rosenthal, I.M.; Weiss, R.E.; Jhiang, S.M.; Burant, C.; Refetoff, S. Congenital hypothyroidism due to mutations in the sodium/iodide symporter. Identification of a nonsense mutation producing a downstream cryptic 3' splice site. *J. Clin. Invest.* **1998**, *101*, 1028–1035, doi:10.1172/JCI1504.
66. Xie, L.; Innis, S.M. Genetic Variants of the FADS1 FADS2 Gene Cluster Are Associated with Altered (n-6) and (n-3) Essential Fatty Acids in Plasma and Erythrocyte Phospholipids in Women during Pregnancy and in Breast Milk during Lactation. *J. Nutr.* **2008**, *138*, 2222–2228, doi:10.3945/jn.108.096156.

67. Moossavi, S.; Atakora, F.; Miliku, K.; Sepehri, S.; Robertson, B.; Duan, Q.L.; Becker, A.B.; Mandhane, P.J.; Turvey, S.E.; Moraes, T.J.; et al. Integrated Analysis of Human Milk Microbiota With Oligosaccharides and Fatty Acids in the CHILd Cohort. *Front. Nutr.* **2019**, *6*, 58, doi:10.3389/fnut.2019.00058.
68. Smith-Brown, P.; Morrison, M.; Krause, L.; Davies, P.S.W. Mothers secretor status affects development of childrens microbiota composition and function: A pilot study. *PLoS ONE* **2016**, *11*, doi:10.1371/journal.pone.0161211.
69. Azad, M.B.; Robertson, B.; Atakora, F.; Becker, A.B.; Subbarao, P.; Moraes, T.J.; Mandhane, P.J.; Turvey, S.E.; Lefebvre, D.L.; Sears, M.R.; et al. Human Milk Oligosaccharide Concentrations Are Associated with Multiple Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices. *J. Nutr.* **2018**, *148*, 1733–1742, doi:10.1093/jn/nxy175.
70. Charbonneau, M.R.; O'donnell, D.; Blanton, L. V.; Lebrilla, C.; Mills, D.A.; Correspondence, J.I.G.; Totten, S.M.; Davis, J.C.C.; Barratt, M.J.; Cheng, J.; et al. Sialylated Milk Oligosaccharides Promote Microbiota-Dependent Growth in Models of Infant Undernutrition Article Sialylated Milk Oligosaccharides Promote Microbiota-Dependent Growth in Models of Infant Undernutrition. *Cell* **2016**, *164*, 859–871, doi:10.1016/j.cell.2016.01.024.
71. Cabrera-Rubio, R.; Kunz, C.; Rudloff, S.; García-Mantrana, I.; Crehuá-Gaudiza, E.; Martínez-Costa, C.; Collado, M.C. Association of Maternal Secretor Status and Human Milk Oligosaccharides With Milk Microbiota. *J. Pediatr. Gastroenterol. Nutr.* **2019**, *68*, 256–263, doi:10.1097/MPG.0000000000002216.
72. Demmelmair, H.; Jiménez, E.; Collado, M.C.; Salminen, S.; McGuire, M.K. Maternal and Perinatal Factors Associated with the Human Milk Microbiome. *Curr. Dev. Nutr.* **2020**, *4*, doi:10.1093/CDN/NZAA027.
73. Lewis, Z.T.; Totten, S.M.; Smilowitz, J.T.; Popovic, M.; Parker, E.; Lemay, D.G.; Van Tassell, M.L.; Miller, M.J.; Jin, Y.S.; German, J.B.; et al. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. *Microbiome* **2015**, *3*, 1–21, doi:10.1186/s40168-015-0071-z.
74. Semba, R.D.; Zhang, P.; Gonzalez-Freire, M.; Moaddel, R.; Trehan, I.; Maleta, K.M.; Ordiz, M.I.; Ferrucci, L.; Manary, M.J. The association of serum choline with linear growth failure in young children from rural Malawi. *Am. J. Clin. Nutr.* **2016**, *104*, 191–197, doi:10.3945/ajcn.115.129684.
75. Holmes-McNary, M.Q.; Cheng, W.L.; Mar, M.H.; Fussell, S.; Zeisel, S.H. Choline and choline esters in human and rat milk and in infant formulas. *Am. J. Clin. Nutr.* **1996**, *64*, 572–576, doi:10.1093/ajcn/64.4.572.
76. Zeisel, S.H.; Klatt, K.C.; Caudill, M.A. Choline. *Adv. Nutr.* **2018**, *9*, 58–60, doi:10.1093/advances/nmx004.
77. MTHFD1 Gene Genetics Home Reference NIH. Available online: <https://ghr.nlm.nih.gov/gene/MTHFD1#normalfunction> (accessed on 22 April 2020).
78. Rillema, J.A. Hormone Regulation of Choline Uptake and Incorporation in Mouse Mammary Gland Explants. *Exp. Biol. Med.* **2004**, *229*, 323–326, doi:10.1177/153537020422900406.
79. Sharp, J.A.; Lefevre, C.; Watt, A.; Nicholas, K.R. Analysis of human breast milk cells: Gene expression profiles during pregnancy, lactation, involution, and mastitic infection. *Funct. Integr. Genom.* **2016**, *16*, 297–321, doi:10.1007/s10142-016-0485-0.
80. Hou, J.; Fang, F.; An, X.; Yan, Y.; Ma, T.; Han, P.; Meng, F.; Song, Y.; Wang, J.; Cao, B. Polymorphisms of PRLR and FOLR1 genes and association with milk production traits in goats. *Genet. Mol. Res.* **2014**, *13*, 2555–2562, doi:10.4238/2014.January.24.1.
81. Ford, J.E. Some observations on the possible nutritional significance of vitamin B 12-and folate-binding proteins in milk. *Br. J. Nutr.* **1974**, *31*, 243–257, doi:10.1079/bjn19740030.
82. Mason, J.B.; Selhub, J. Folate-binding protein and the absorption of folic acid in the small intestine of the suckling rat. *Am. J. Clin. Nutr.* **1988**, *48*, 620–625, doi:10.1093/ajcn/48.3.620.
83. Visentin, M.; Diop-Bove, N.; Zhao, R.; Goldman, I.D. The Intestinal Absorption of Folates. *Annu. Rev. Physiol.* **2014**, *76*, 251–274, doi:10.1146/annurev-physiol-020911-153251.
84. Zhao, R.; Goldman, I.D. The proton-coupled folate transporter: Physiological and pharmacological roles. *Curr. Opin. Pharmacol.* **2013**, *13*, 875–880.
85. Page, R.; Wong, A.; Arbuckle, T.E.; Macfarlane, A.J. The MTHFR 677C>T polymorphism is associated with unmetabolized folic acid in breast milk in a cohort of Canadian women. *Am. J. Clin. Nutr.* **2019**, *110*, 401–409, doi:10.1093/ajcn/nqz056.
86. Delplanque, B.; Gibson, R.; Koletzko, B.; Lapillonne, A.; Strandvik, B. Lipid Quality in Infant Nutrition: Current Knowledge and Future Opportunities. *J. Pediatr. Gastroenterol. Nutr.* **2015**, *61*, 8–17.
87. Martin, C.; Ling, P.-R.; Blackburn, G. Review of Infant Feeding: Key Features of Breast Milk and Infant Formula. *Nutrients* **2016**, *8*, 279, doi:10.3390/nu8050279.

88. Koletzko, B.; Agostoni, C.; Bergmann, R.; Ritzenthaler, K.; Shamir, R. Physiological aspects of human milk lipids and implications for infant feeding: A workshop report. *Acta Paediatr.* **2011**, *100*, 1405–1415, doi:10.1111/j.1651-2227.2011.02343.x.
89. Pacheco-Pappenheim, S.; Yener, S.; van Valenberg, H.J.F.; Tzompa-Sosa, D.A.; Bovenhuis, H. The DGAT1 K232A polymorphism and feeding modify milk fat triacylglycerol composition. *J. Dairy Sci.* **2019**, *102*, 6842–6852, doi:10.3168/jds.2019-16554.
90. Tăbăran, A.; Balteanu, V.A.; Gal, E.; Pusta, D.; Mihaiu, R.; Dan, S.D.; Tăbăran, A.F.; Mihaiu, M. Influence of DGAT1 K232A polymorphism on milk fat percentage and fatty acid profiles in Romanian holstein cattle. *Anim. Biotechnol.* **2015**, *26*, 105–111, doi:10.1080/10495398.2014.933740.
91. Rincon, G.; Islas-Trejo, A.; Castillo, A.R.; Bauman, D.E.; German, B.J.; Medrano, J.F. Polymorphisms in genes in the SREBP1 signalling pathway and SCD are associated with milk fatty acid composition in Holstein cattle. *J. Dairy Res.* **2012**, *79*, 66–75, doi:10.1017/S002202991100080X.
92. Cruz, V.A.R.; Oliveira, H.R.; Brito, L.F.; Fleming, A.; Larmer, S.; Miglior, F.; Schenkel, F.S. Genome-Wide Association Study for Milk Fatty Acids in Holstein Cattle Accounting for the DGAT1 Gene Effect. *Animals* **2019**, *9*, 997, doi:10.3390/ani9110997.
93. Zheng, X.R.; Jiang, L.; Ning, C.; Hu, Z.Z.; Zhou, L.; Yu, Y.; Zhang, S.L.; Liu, J.F. A novel mutation in the promoter region of RPL8 regulates milk fat traits in dairy cattle by binding transcription factor Pax6. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **2019**, *1864*, doi:10.1016/j.bbalip.2019.158528.
94. Klein, S.L.; Scheper, C.; Brügemann, K.; Swalve, H.H.; König, S. Phenotypic relationships, genetic parameters, genome-wide associations, and identification of potential candidate genes for ketosis and fat-to-protein ratio in German Holstein cows. *J. Dairy Sci.* **2019**, *102*, 6276–6287, doi:10.3168/jds.2019-16237.
95. Zielke, L.G.; Bortfeldt, R.H.; Reissmann, M.; Tetens, J.; Thaller, G.; Brockmann, G.A. Impact of Variation at the FTO Locus on Milk Fat Yield in Holstein Dairy Cattle. *PLoS ONE* **2013**, *8*, doi:10.1371/journal.pone.0063406.
96. Winter, A.; Krämer, W.; Werner, F.A.O.; Kollers, S.; Kata, S.; Durstewitz, G.; Buitkamp, J.; Womack, J.E.; Thaller, G.; Fries, R. Association of a lysine-232/alanine polymorphism in a bovine gene encoding acyl-CoA:Diacylglycerol acyltransferase (DGAT1) with variation at a quantitative trait locus for milk fat content. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 9300–9305, doi:10.1073/pnas.142293799.
97. Grisart, B.; Coppieters, W.; Farnir, F.; Karim, L.; Ford, C.; Berzi, P.; Cambisano, N.; Mni, M.; Reid, S.; Simon, P.; et al. Positional candidate cloning of a QTL in dairy cattle: Identification of a missense mutation in the bovine DGAT1 gene with major effect on milk yield and composition. *Genome Res.* **2002**, *12*, 222–231, doi:10.1101/gr.224202.
98. Spelman, R.J.; Ford, C.A.; McElhinney, P.; Gregory, G.C.; Snell, R.G. Characterization of the DGAT1 gene in the New Zealand dairy population. *J. Dairy Sci.* **2002**, *85*, 3514–3517, doi:10.3168/jds.S0022-0302(02)74440-8.
99. Thaller, G.; Kramer, W.; Winter, A.; Kaupe, B.; Erhardt, G.; Fries, R. Effects of DGAT1 variants on milk production traits in German cattle breeds1. *J. Anim. Sci.* **2003**, *81*, 1911–1918, doi:10.2527/2003.8181911x.
100. Weller, J.I.; Golik, M.; Seroussi, E.; Ezra, E.; Ron, M. Population-wide analysis of a QTL affecting milk-fat production in the Israeli Holstein population. *J. Dairy Sci.* **2003**, *86*, 2219–2227, doi:10.3168/jds.S0022-0302(03)73812-0.
101. Gautier, M.; Capitan, A.; Fritz, S.; Eggen, A.; Boichard, D.; Druet, T. Characterization of the DGAT1 K232A and variable number of tandem repeat polymorphisms in French dairy cattle. *J. Dairy Sci.* **2007**, *90*, 2980–2988, doi:10.3168/jds.2006-707.
102. Fürbass, R.; Winter, A.; Fries, R.; Kühn, C. Alleles of the bovine DGAT1 variable number of tandem repeat associated with a milk fat QTL at chromosome 14 can stimulate gene expression. *Physiol. Genom.* **2006**, *25*, 116–120, doi:10.1152/physiolgenomics.00145.2005.
103. Berry, D.P.; Howard, D.; O’Boyle, P.; Waters, S.; Kearney, J.F.; McCabe, M. Associations between the K232A polymorphism in the diacylglycerol-O-transferase 1 (DGAT1) gene and performance in Irish Holstein-Friesian dairy cattle. *Irish J. Agric. Food Res.* **2010**, *49*, 1–9.
104. Gluchowski, N.L.; Chitraju, C.; Picoraro, J.A.; Mejhert, N.; Pinto, S.; Xin, W.; Kamin, D.S.; Winter, H.S.; Chung, W.K.; Walther, T.C.; et al. Identification and characterization of a novel DGAT1 missense mutation associated with congenital diarrhea. *J. Lipid Res.* **2017**, *58*, 1230–1237, doi:10.1194/jlr.P075119.

105. Haas, J.T.; Winter, H.S.; Lim, E.; Kirby, A.; Blumenstiel, B.; DeFelice, M.; Gabriel, S.; Branski, D.; Grueter, C.A.; Toporovski, M.S.; et al. DGAT1 mutation is linked to a congenital diarrheal disorder. *J. Clin. Investig.* **2012**, *122*, 4680–4684, doi:10.1172/JCI64873.
106. Ding, Z.; Liu, G.L.; Li, X.; Chen, X.Y.; Wu, Y.X.; Cui, C.C.; Zhang, X.; Yang, G.; Xie, L. Association of polyunsaturated fatty acids in breast milk with fatty acid desaturase gene polymorphisms among Chinese lactating mothers. *Prostaglandins Leukot. Essent. Fat. Acids* **2016**, *109*, 66–71, doi:10.1016/j.plefa.2016.03.009.
107. Lattka, E.; Rzehak, P.; Szabó, É.; Jakobik, V.; Weck, M.; Weyermann, M.; Grallert, H.; Rothenbacher, D.; Heinrich, J.; Brenner, H.; et al. Genetic variants in the FADS gene cluster are associated with arachidonic acid concentrations of human breast milk at 1.5 and 6 mo postpartum and influence the course of milk dodecanoic, tetracosenoic, and trans-9-octadecenoic acid concentrations over the duration of lactation. *Am. J. Clin. Nutr.* **2011**, *93*, 382–391, doi:10.3945/ajcn.110.004515.
108. Miliku, K.; Duan, Q.L.; Moraes, T.J.; Becker, A.B.; Mandhane, P.J.; Turvey, S.E.; Lefebvre, D.L.; Sears, M.R.; Subbarao, P.; Field, C.J.; et al. Human milk fatty acid composition is associated with dietary, genetic, sociodemographic, and environmental factors in the CHILD Cohort Study. *Am. J. Clin. Nutr.* **2019**, *110*, 1370–1383, doi:10.1093/ajcn/nqz229.
109. Morales, E.; Bustamante, M.; Gonzalez, J.R.; Guxens, M.; Torrent, M.; Mendez, M.; Garcia-Esteban, R.; Julvez, J.; Forns, J.; Vrijheid, M.; et al. Genetic Variants of the FADS Gene Cluster and ELOVL Gene Family, Colostrums LC-PUFA Levels, Breastfeeding, and Child Cognition. *PLoS ONE* **2011**, *6*, e17181, doi:10.1371/journal.pone.0017181.
110. Wu, Y.; Wang, Y.; Tian, H.; Lu, T.; Yu, M.; Xu, W.; Liu, G.; Xie, L. DHA intake interacts with ELOVL2 and ELOVL5 genetic variants to influence polyunsaturated fatty acids in human milk. *J. Lipid Res.* **2019**, *60*, 1043–1049, doi:10.1194/jlr.M090951.
111. Thijs, C.; Müller, A.; Rist, L.; Kummeling, I.; Snijders, B.E.P.; Huber, M.; Van Ree, R.; Simões-Wüst, A.P.; Dagnelie, P.C.; Van Den Brandt, P.A. Fatty acids in breast milk and development of atopic eczema and allergic sensitisation in infancy. *Allergy* **2011**, *66*, 58–67, doi:10.1111/j.1398-9995.2010.02445.x.
112. Chowanadisai, W.; Kelleher, S.L.; Nemeth, J.F.; Yachetti, S.; Kuhlman, C.F.; Jackson, J.G.; Davis, A.M.; Lien, E.L.; Lönnnerdal, B. Detection of a single nucleotide polymorphism in the human α -lactalbumin gene: Implications for human milk proteins. *J. Nutr. Biochem.* **2005**, *16*, 272–278, doi:10.1016/j.jnutbio.2004.12.010.
113. Nilsen, H.; Olsen, H.G.; Hayes, B.; Sehested, E.; Svendsen, M.; Nome, T.; Meuwissen, T.; Lien, S. Casein haplotypes and their association with milk production traits in Norwegian Red cattle. *Genet. Sel. Evol.* **2009**, *41*, doi:10.1186/1297-9686-41-24.
114. Alim, M.A.; Dong, T.; Xie, Y.; Wu, X.P.; Zhang, Y.; Zhang, S.; Sun, D.X. Effect of polymorphisms in the CSN3 (κ -casein) gene on milk production traits in Chinese Holstein Cattle. *Mol. Biol. Rep.* **2014**, *41*, 7585–7593, doi:10.1007/s11033-014-3648-x.
115. Bode, L.; Raman, A.S.; Murch, S.H.; Rollins, N.C.; Gordon, J.I. Understanding the mother-breastmilk-infant “triad”. *Science* **2020**, *367*, 1070–1072, doi:10.1126/science.aaw6147.
116. Bode, L. Human milk oligosaccharides: Every baby needs a sugar mama. *Glycobiology* **2012**, *22*, 1147–1162, doi:10.1093/glycob/cws074.
117. Lagström, H.; Rautava, S.; Ollila, H.; Kaljonen, A.; Turta, O.; Mäkelä, J.; Yonemitsu, C.; Gupta, J.; Bode, L. Associations between human milk oligosaccharides and growth in infancy and early childhood. *Am. J. Clin. Nutr.* **2020**, *111*, 769–778, doi:10.1093/ajcn/nqaa010.
118. Borewicz, K.; Gu, F.; Saccenti, E.; Hechler, C.; Beijers, R.; de Weerth, C.; van Leeuwen, S.S.; Schols, H.A.; Smidt, H. The association between breastmilk oligosaccharides and faecal microbiota in healthy breastfed infants at two, six, and twelve weeks of age. *Sci. Rep.* **2020**, *10*, 4270, doi:10.1038/s41598-020-61024-z.
119. Bai, Y.; Tao, J.; Zhou, J.; Fan, Q.; Liu, M.; Hu, Y.; Xu, Y.; Zhang, L.; Yuan, J.; Li, W.; et al. Fucosylated Human Milk Oligosaccharides and N-Glycans in the Milk of Chinese Mothers Regulate the Gut Microbiome of Their Breast-Fed Infants during Different Lactation Stages. *mSystems* **2018**, *3*, doi:10.1128/msystems.00206-18.
120. Wacklin, P.; Mä, H.; Alakulppi, N.; Nikkilä, J.; Tenkanen, H.; Rå, J.; Partanen, J.; Aranko, K.; Mä, J. Secretor Genotype (FUT2 gene) Is Strongly Associated with the Composition of Bifidobacteria in the Human Intestine. *PLoS ONE* **2011**, *6*, e20113, doi:10.1371/journal.pone.0020113.
121. Korpela, K.; Salonen, A.; Hickman, B.; Kunz, C.; Sprenger, N.; Kukkonen, K.; Savilahti, E.; Kuitunen, M.; de Vos, W.M. Fucosylated oligosaccharides in mother’s milk alleviate the effects of caesarean birth on infant gut microbiota. *Sci. Rep.* **2018**, *8*, doi:10.1038/s41598-018-32037-6.

122. Davis, J.C.C.; Lewis, Z.T.; Krishnan, S.; Bernstein, R.M.; Moore, S.E.; Prentice, A.M.; Mills, D.A.; Lebrilla, C.B.; Zivkovic, A.M. Growth and Morbidity of Gambian Infants are Influenced by Maternal Milk Oligosaccharides and Infant Gut Microbiota. *Sci. Rep.* **2017**, *7*, doi:10.1038/srep40466.
123. Aakko, J.; Kumar, H.; Rautava, S.; Wise, A.; Autran, C.; Bode, L.; Isolauri, E.; Salminen, S. Human milk oligosaccharide categories define the microbiota composition in human colostrum. *Benef. Microbes* **2017**, *8*, 563–567, doi:10.3920/BM2016.0185.
124. Charbonneau, M.R.; Blanton, L. V.; DiGiulio, D.B.; Relman, D.A.; Lebrilla, C.B.; Mills, D.A.; Gordon, J.I. Human developmental biology viewed from a microbial perspective. *Nature* **2016**, *535*, 48–55, doi:10.1038/nature18845.Human.
125. Robertson, B.M.; Bode, L.; Sharma, A.K.; Becker, A.B.; Mandhane, P.J.; Subbarao, P.; Turvey, S.E.; Lefebvre, Diana, L.; Sears, M.R.; Azad, M.B. Maternal Factors and Human Milk Oligosaccharide Composition in the CHILd Cohort. *FASEB J.* **2017**, *31.1*.
126. Cui, X.; Hou, Y.; Yang, S.; Xie, Y.; Zhang, S.; Zhang, Y.; Zhang, Q.; Lu, X.; Liu, G.E.; Sun, D. Transcriptional profiling of mammary gland in Holstein cows with extremely different milk protein and fat percentage using RNA sequencing. *BMC Genom.* **2014**, *15*, 226, doi:10.1186/1471-2164-15-226.
127. Falk, R.J. Isolated prolactin deficiency: A case report. *Fertil. Steril.* **1992**, *58*, 1060–1062, doi:10.1016/S0015-0282(16)55460-0.
128. Berens, P.D.; Villanueva, M.; Nader, S.; Swaim, L.S. Isolated prolactin deficiency: A possible culprit in lactation failure. *AACE Clin. Case Rep.* **2018**, *4*, e509–e512, doi:10.4158/accr-2018-0132.
129. Iwama, S.; Welt, C.K.; Romero, C.J.; Radovick, S.; Caturegli, P. Isolated Prolactin Deficiency Associated With Serum Autoantibodies Against Prolactin-Secreting Cells. *J. Clin. Endocrinol. Metab.* **2013**, *98*, 3920–3925, doi:10.1210/jc.2013-2411.
130. Saito, T.; Tojo, K.; Oki, Y.; Sakamoto, N.; Matsudaira, T.; Sasaki, T.; Tajima, N. A Case of Prolactin Deficiency with Familial Puerperal Alactogenesis Accompanying Impaired ACTH Secretion. *Endocr. J.* **2006**, *54*, 59–62, doi:10.1507/endocrj.k05-163.
131. Moriwaki, M.; Welt, C. MON-434 Familial Alactogenesis Associated with a Prolactin Mutation. *J. Endocr. Soc.* **2019**, *3*, doi:10.1210/js.2019-mon-434.
132. Brym, P.; Kamiński, S.; Wójcik, E. Polymorphism within the Bovine Prolactin Receptor Gene (PRLR); *Anim. Sci. Pap. Rep.* **2005**, *23*, no. 1, 61–66
133. Lü, A.; Hu, X.; Chen, H.; Dong, Y.; Zhang, Y.; Wang, X. Novel SNPs of the bovine PRLR gene associated with milk production traits. *Biochem. Genet.* **2011**, *49*, 177–189, doi:10.1007/s10528-010-9397-1.
134. Zhang, J.; Zan, L.; Fang, P.; Zhang, F.; Shen, G.; Tian, W. Genetic variation of PRLR gene and association with milk performance traits in dairy cattle. *Can. J. Anim. Sci.* **2008**, *88*, 33–39, doi:10.4141/CJAS07052.
135. Kelly, P.A.; Binart, N.; Lucas, B.; Bouchard, B.; Goffin, V. Implications of Multiple Phenotypes Observed in Prolactin Receptor Knockout Mice. *Front. Neuroendocr.* **2001**, *22*, 140–145, doi:10.1006/frne.2001.0212.
136. Newey, P.J.; Gorvin, C.M.; Cleland, S.J.; Willberg, C.B.; Bridge, M.; Azharuddin, M.; Drummond, R.S.; van der Merwe, P.A.; Klenerman, P.; Bountra, C.; et al. Mutant Prolactin Receptor and Familial Hyperprolactinemia. *N. Engl. J. Med.* **2013**, *369*, 2012–2020, doi:10.1056/NEJMoa1307557.
137. Majumdar, A.; Mangal, N.S. Hyperprolactinemia. *J. Hum. Reprod. Sci.* **2013**, *6*, 168–175.
138. Kobayashi, T.; Usui, H.; Tanaka, H.; Shozu, M. Variant Prolactin Receptor in Agalactia and Hyperprolactinemia. *N. Engl. J. Med.* **2018**, *379*, 2230–2236, doi:10.1056/NEJMoa1805171.
139. Hlusko, L.J.; Carlson, J.P.; Chaplin, G.; Elias, S.A.; Hoffecker, J.F.; Huffman, M.; Jablonski, N.G.; Monson, T.A.; O'Rourke, D.H.; Pilloud, M.A.; et al. Environmental selection during the last ice age on the mother-to-infant transmission of vitamin D and fatty acids through breast milk. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E4426–E4432, doi:10.1073/pnas.1711788115.
140. De Amici, D.; Gasparoni, A.; Guala, A.; Klersy, C. Does ethnicity predict lactation? A study of four ethnic communities. *Eur. J. Epidemiol.* **2001**, *17*, 357–362, doi:10.1023/a:1012731713393.
141. Seo, Y.A.; Kelleher, S.L. Functional analysis of two single nucleotide polymorphisms in SLC30A2 (ZnT2): Implications for mammary gland function and breast disease in women. *Physiol. Genom.* **2010**, *42A*, 219–227, doi:10.1152/physiolgenomics.00137.2010.
142. Mathias, R.A.; Pani, V.; Chilton, F.H. Genetic Variants in the FADS Gene: Implications for Dietary Recommendations for Fatty Acid Intake. *Curr. Nutr. Rep.* **2014**, *3*, 139–148.
143. Ekmekci, A.; Cirak, M.Y. Nutrigenomics and nutrigenetics. Chapter 14 in *Advances in Food Biochemistry*; CRC Press: Boca Raton, FL, 2009; pp. 457–475, ISBN 9781420007695.

144. Sales, N.M.R.; Pelegrini, P.B.; Goersch, M.C. Nutrigenomics: Definitions and advances of this new science. *J. Nutr. Metab.* **2014**, *2014*, doi:10.1155/2014/202759.
145. Tannock, I.F.; Hickman, J.A. Limits to Personalized Cancer Medicine. *N. Engl. J. Med.* **2016**, *375*, 1289–1295.
146. Turnbull, A.K. Personalized medicine in cancer: Where are we today? *Future Oncol.* **2015**, *11*, 2795–2798.
147. Ordovas, J.M.; Ferguson, L.R.; Tai, E.S.; Mathers, J.C. Personalised nutrition and health. *BMJ* **2018**, *361*, doi:10.1136/bmj.k2173.
148. Bashiardes, S.; Abdeen, S.K.; Elinav, E. Personalized Nutrition. *J. Pediatr. Gastroenterol. Nutr.* **2019**, *69*, 633–638, doi:10.1097/MPG.0000000000002491.
149. Zeevi, D.; Korem, T.; Zmora, N.; Israeli, D.; Rothschild, D.; Weinberger, A.; Ben-Yacov, O.; Lador, D.; Avnit-Sagi, T.; Lotan-Pompan, M.; et al. Personalized Nutrition by Prediction of Glycemic Responses. *Cell* **2015**, *163*, 1079–1094, doi:10.1016/j.cell.2015.11.001.
150. Hietaranta-Luoma, H.L.; Tahvonen, R.; Iso-Touru, T.; Puolijoki, H.; Hopia, A. An intervention study of individual, apoe genotype-based dietary and physical-activity advice: Impact on health behavior. *J. Nutr. Nutr.* **2014**, *7*, 161–174, doi:10.1159/000371743.
151. Carpenter, D.; Dhar, S.; Mitchell, L.M.; Fu, B.; Tyson, J.; Shwan, N.A.A.; Yang, F.; Thomas, M.G.; Armour, J.A.L. Obesity, starch digestion and amylase: Association between copy number variants at human salivary (AMY1) and pancreatic (AMY2) amylase genes. *Hum. Mol. Genet.* **2015**, *24*, 3472–3480, doi:10.1093/hmg/ddv098.
152. Powe, C.E.; Knott, C.D.; Conklin-Brittain, N. Infant sex predicts breast milk energy content. *Am. J. Hum. Biol.* **2010**, *22*, 50–54, doi:10.1002/ajhb.20941.
153. Riskin, A.; Almog, M.; Peri, R.; Halasz, K.; Srugo, I.; Kessel, A. Changes in immunomodulatory constituents of human milk in response to active infection in the nursing infant. *Pediatr. Res.* **2012**, *71*, 220–225, doi:10.1038/pr.2011.34.
154. GarcíA-Lino, A.M.; Álvarez-Fernández, I.; Blanco-Paniagua, E.; Merino, G.; Álvarez, A.I. Transporters in the Mammary gland—Contribution to presence of nutrients and drugs into milk. *Nutrients* **2019**, *11*, 2372.
155. Golan, Y.; Alhadeff, R.; Warshel, A.; Assaraf, Y.G. ZnT2 is an electroneutral proton-coupled vesicular antiporter displaying an apparent stoichiometry of two protons per zinc ion. *PLoS Comput. Biol.* **2019**, *15*, e1006882, doi:10.1371/journal.pcbi.1006882.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).